Malignancy After Heart Transplantation

Chen, Po‐Lin; Chang, Hsiao-Huang; Chen, I‐Ming; Lai, Shiau Ting; Shih, Chun-Che; Weng, Zen-Chung; Hsieh, Yun Cheng; Yang, An-Hang

doi:10.1016/s1726-4901(09)70434-4

Cited by 20 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6) The clinical characteristics of HTx recipients, surgical procedure at the time of HTx surgery, immunosuppressive regimen, and outcome after HTx were retrospectively reviewed. The incidences of major complications after HTx, such as hypertension, 11,12) diabetes, 13) hyperlipidemia, 14,15) renal insufficiency, 16) and malignancy 17) were also reviewed. Donor-related information such as gender, age, or cause of brain death was not included due to the difficulty of obtaining informed consent from the family of the deceased.…”

Section: Methodsmentioning

confidence: 99%

Clinical Course and Outcome of Heart Transplant Recipients Single Center Experience at the National Cardiovascular Center in Japan

et al. 2010

View full text Add to dashboard Cite

SummaryThe number of heart transplant (HTx) surgeries in Japan is expected to increase under the Revised Organ Transplant Law. To date, among 69 HTx surgeries performed in Japan, 27 operations (39.1%) were performed at our institution, the National Cardiovascular Center (NCVC), located in Osaka. We have reviewed the outcomes of HTx conducted at NCVC during a 10 year period (May 1999 to January 2009). Among 27 heart transplant recipients at NCVC, the clinical charts of 26 recipients whose post-HTx period exceeded 1 year were retrospectively reviewed and compared to data from the International Society for Heart and Lung Transplantation (ISHLT) Registry. The survival rate of our recipients was 96.2% at 10.8 years, which was excellent even compared to the ISHLT Registry. The immunosuppressive regimen at NCVC was equivalent to that of the ISHLT Registry, except for more frequent use of Muromonab-CD3 (26.9% versus 3.3%, P < 0.0001) and an initial CSA-based regimen (65.3% versus 34.4%, P < 0.001). The drug we use for induction therapy has been recently changed from Muromonab-CD3 to Basiliximab. The incidences of post-HTx hypertension, diabetes, hyperlipidemia, and renal insufficiency were significantly less in patients at NCVC compared to those in the ISHLT Registry, however, the incidence of transplant coronary artery disease (TxCAD) was almost identical. Clinical review of post-HTx outcome at NCVC can provide useful information for Japanese transplant cardiologists who will engage in HTx management. (Int Heart J 2010; 51: 264-271)

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical Course and Outcome of Heart Transplant Recipients Single Center Experience at the National Cardiovascular Center in Japan

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, these results were not sta tistically significant in the multivariate analysis. 16 In contrast, Chen and associates 6 linked tacrolimus with an increased risk of posttransplant malignancies.…”

Section: Tacrolimusmentioning

confidence: 99%

“…9 The pathogenesis of skin cancer is multifactorial, with extrinsic and intrinsic factors both playing roles in malignancy development. Ultraviolet radiation appears to be the most important responsible factor, 6 as skin cancers are likely to develop on sun-exposed areas and in transplant recipients with high sun exposure after transplant (> 10 000 hours). 28,29 The incidence of skin cancer is proportional to the level of immunosuppression, with rejection episodes in the first year resulting in higher incidence.…”

Section: Malignancies After Heart Transplantmentioning

confidence: 99%

“…4,5 With the advent of potent immunosuppressive therapies and evolution of posttransplant patient care, the survival rates of recipients and grafts have improved significantly, turning concern to long-term complications. 6 Posttransplant malignancies and graft vasculopathy are the two major long-term complications and causes of death in heart transplant patients. Advanced age, male sex, preexisting malignancy, immunosuppressive therapy, and oncogenic viral infection are causes of cancer in heart transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

Lateef

Basit²,

Abbasi³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Along with graft vasculopathy, malignancies comprise a major complication after heart transplant, with a rate of occurrence of 39.1% in 10 years. Skin cancers and posttransplant lymphoproliferative disorder are more common in adults, whereas lymphoma is more often shown in children. A major cause of malignancies after heart transplant is the use of increased doses of prophylactics needed during immunosuppressive therapy. Data, however, are scarce regarding the association between a particular immunosuppressive drug and a posttransplant malignancy. Compared with the general population, recipients have a higher incidence of malignancies after heart transplant, with an early onset and more aggressive disease. Solid tumors known to occur in heart transplant recipients include lung cancer, bladder and prostate carcinoma, adenocarcinoma of the oral cavity, stomach cancer, and bowel cancer, although the incidence is rare. The risk factors for development of a malignancy after heart transplant are the same as for the nontransplant population.

show abstract

“…[1][2][3][4] Further, transplant patients generally have poorer disease-specific survival than the general population. [1][2][3][4] Further, transplant patients generally have poorer disease-specific survival than the general population.…”

mentioning

confidence: 99%